omalizumab

New treatments on the horizonEmerging therapies are showing impressive efficacy and good tolerability, according to one dermatologist.
Off-label systemic immunomodulators useful for various indicationsAlthough many systemic immunomodulators are approved for psoriasis, their mechanisms of action suggest they have utility in indications ranging from atopic dermatitis (AD) to chronic urticaria. Understanding a systemic immunomodulator’s mechanism of action provides a theoretical basis for uses beyond its labeled indication.
Asthma drug relieves chronic hivesThe asthma drug omalizumab may provide symptom relief to patients with chronic idiopathic urticaria, results of a recently published study suggest.
Immunotherapy for food allergy: Promise and progress
Immunotherapy for food allergy: Promise and progressAllergen-specific immunotherapy, although still experimental, is becoming an area of active research for treatment of food allergy in children.
FDA approves Xolair for chronic idiopathic urticariaThe Food and Drug Administration has approved Xolair (omalizumab, Novartis) for the treatment of chronic idiopathic urticaria in patients ages 12 and older.
Asthma drug calms chronic urticariaThe asthma medication omalizumab helps to calm chronic urticaria in patients who had failed standard therapy, according to results of a phase 3 study.